Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab Safety and PK Study in Advanced Solid Tumors
NCT02794571Phase 1Completed
- Sponsor
- Genentech
- Start
- May 2016
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
Phase 1, open-label trial of tiragolumab in solid tumor (advanced stage) (12 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities, Percentage of Participants with Adverse Events and 2 more. Started May 2016; status: completed.
02
Drugs
tiragolumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02794571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794571.